Pharma Social Media: An ABPI-Aware Drafting and Review Guide

Social media has become one of the most scrutinised channels in pharmaceutical marketing. The ABPI Code of Practice 2024 does not carve out a separate rulebook for LinkedIn, X, or Instagram — every post, comment, and reshare is held to the same standards as a printed detail aid. This guide outlines audience and evidence checks to consider before submitting social copy to your reviewers. It cannot establish whether a particular post is acceptable.

What the ABPI Code of Practice Covers on Social Media

The ABPI Code of Practice is the self-regulatory framework governing the promotion of prescription medicines to UK healthcare professionals and communication with the public. Clause 5 (high standards), Clause 6 (accuracy and balance) and Clause 26 (public-facing communications) apply to social media in full.

Read the current Code alongside PMCPA social media guidance. Check whether the communication is promotional, who can access it, and whether statements and the overall presentation are accurate and supportable. Do not assume an educational label makes product promotion non-promotional.

Fair Balance in a 280-Character World

Review the overall balance of a communication, not only individual claims. Applicable information requirements depend on the material, audience and jurisdiction. A short caption or generic disclaimer does not make an otherwise misleading message acceptable.

Questions to discuss with your reviewers:

• Check that benefit statements and relevant limitations or risks are presented appropriately in the communication as a whole.
• If character limits force a trade-off, drop the claim, not the safety information.
• Confirm the prescribing-information and other mandatory-information requirements for this specific material; do not assume a link alone is sufficient.
• Treat images and video captions as copy — they carry the same obligations as body text.

Audience Targeting: HCP vs Public

The Code draws a hard line between healthcare professionals and the public. Prescription-only medicine promotion is permitted to the first group and prohibited to the second.

On social media, audience is defined by who can see the post, not who you intended to reach. That has practical consequences:

• Open accounts on X, Instagram, TikTok and Facebook are treated as public-facing. Do not promote prescription medicines on them.
• A professional platform such as LinkedIn is not automatically an HCP-only channel. Assess access, audience controls and onward sharing with your reviewers.
• For paid activity, assess actual access and audience verification rather than relying on job-title targeting alone.
• Assess company responsibility for employee and contracted expert activity, including reshares, under PMCPA guidance and your internal policy.

Disease Awareness Without Product Promotion

Public-facing disease-awareness communication must not promote prescription-only medicines directly or indirectly. That includes indirect identification through images, hashtags, or account handles that map one-to-one to a product.

A disease-awareness draft can discuss the condition and seeking appropriate advice. Review names, images, links and surrounding account content for any direct or indirect prescription-medicine promotion; a disease-only caption is not enough by itself.

Channel-Specific Pitfalls

Each platform has quirks that create Code risk if you do not plan for them:

• LinkedIn: employee reshares of promotional posts extend your audience beyond HCPs — assume public reach unless controls exist.
• X: threads can separate a claim from its safety information. Keep both in the first post.
• Instagram and TikTok: captions are truncated in-feed. Put safety information before the fold, not after 'more'.
• Comments and DMs: assess replies in context and use an agreed moderation, medical-information and adverse-event escalation process. Not every reply is promotional, but an informal format does not remove responsibilities.

A Review-Ready Checklist

Before a social post enters MLR, run it through this list:

• Is the audience clearly HCP or public, and does the content match?
• Are benefits, limitations and risk information balanced appropriately for the material and applicable requirements?
• Is every claim substantiated by a referenced source?
• Are images, captions, hashtags and alt text held to the same standard as body copy?
• Is the adverse event reporting statement present where required?
• Have reshares, boosts, and employee amplification been approved as part of the same review?

How RegScribe Helps

RegScribe helps draft healthcare social media content from a supplied brief, audience and channel. Its optional Compliance Checker can flag potential claims, evidence gaps and regulatory considerations for human review. Output still needs checking against the current Code, approved product information and the supplied evidence.

It is a drafting aid, not a substitute for review. No template or automated pre-review establishes regulatory approval or guarantees compliance.